IncyteWBO:INCY 87 EV-to-FCF is 13.96 as of Jul. 11, 2026, which is 33% below its 10-year median of 20.73. GuruFocus rates WBO:INCY with a GF Score™ of 87/100 and a GF Value™ of €59.10. The stock has 4 warning signs investors should review. Among 330 Biotechnology companies, Incyte ranks better than 54.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Incyte's Enterprise Value is €16,985 Mil.
Incyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €1,217 Mil. Therefore, Incyte's EV-to-FCF for today is 13.96.
The historical rank and industry rank for Incyte's EV-to-FCF or its related term are showing as below:
WBO:INCY'
s EV-to-FCF Range Over the Past 10 Years
Min: -12563.98 Med: 20.73 Max: 868.4
Current: 13.87
During the past 13 years, the highest EV-to-FCF of Incyte was 868.40. The lowest was -12563.98. And the median was 20.73.
WBO:INCY's EV-to-FCF is ranked better than 54.55% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs WBO:INCY: 13.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-11), Incyte's stock price is €70.36.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €6.086. Therefore, Incyte's PE Ratio (TTM) for today is 11.56.
Incyte (WBO:INCY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Incyte's share price for today is €70.36.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.086.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Incyte EV-to-FCF Related Terms
Incyte EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Incyte's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:INCY vs INSM, BNTX, ROIV: EV-to-FCF Comparison
For the Biotechnology subindustry, Incyte's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Incyte's EV-to-FCF falls into.
Incyte's current Enterprise Value is €16,985 Mil.
Incyte's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,217 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (WBO:INCY) has a EV-to-FCF of 13.96 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Incyte and its competitors. This is 33% below median its historical median of 20.73. According to the industry distribution chart, Incyte ranks #150 out of 330 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Incyte's EV-to-FCF too high?
Incyte's current EV-to-FCF of 13.96 is 33% below median its 10-year median of 20.73. The Biotechnology industry median EV-to-FCF is 16.36. Incyte's value of 13.96 is 14.7% below this industry median. Based on the distribution chart, Incyte ranks #150 out of 330 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Incyte has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Incyte's EV-to-FCF compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #150 out of 330 companies for EV-to-FCF. This puts Incyte in the upper half of its industry. The industry median EV-to-FCF is 16.36. Incyte's value of 13.96 is 14.7% below this benchmark. While the company's 10-year median is 20.73 vs. the industry median of 16.36, Incyte has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incyte's current EV-to-FCF of 13.96 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Incyte and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current EV-to-FCF is 13.96, which is 33% below median its own 10-year median of 20.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Incyte (WBO:INCY) has a current EV-to-FCF of 13.96. The stock's GF Value™ is €59.10, compared to a current price of €70.36 — trading 19.1% above its estimated fair value. The current EV-to-FCF is 13.96, which is 33% below median its 10-year median of 20.73 and 14.7% below the Biotechnology industry median of 16.36. Incyte's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Incyte (WBO:INCY), the current EV-to-FCF is 13.96 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (WBO:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of €70.36 is trading 19.1% above its estimated GF Value™ of €59.10.
Key valuation signals for WBO:INCY:
EV-to-FCF: 13.96 (33% below median its 10-year median of 20.73)
GF Value™: €59.10 vs. price of €70.36 (19.1% above fair value)
Industry Position: 14.7% below the Biotechnology median (#150 of 330)
No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
87GF Score
Get the complete analysis for WBO:INCY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:INCY has been successfully added to your 
